Prevention Of Migraine Attacks — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for prevention of migraine attacks. 3 active patents protecting 1 drugs from 1+ originators. First major cliff: 2033. Daily refresh.

1
Approved drugs
3
Active US patents
43/100
Avg vulnerability
$1.4B
Annual revenue covered

Originators in Prevention Of Migraine Attacks

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Pfizer 3 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating prevention of migraine attacks. Each bar = one year. Y-axis scaled to peak year (1 patents).

1
33
1
34
1
39

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Nurtec Odt
Rimegepant Sulfate
 Pfizer 3 43 $1.4B 2033-02-25

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8314117 Nurtec Odt method of use 62 2034-02-27
11083724 Nurtec Odt method of use 62 2039-03-25
8759372 Nurtec Odt composition of matter 4 2033-02-25

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8759372 Nurtec Odt composition of matter 4 2033-02-25
11083724 Nurtec Odt method of use 62 2039-03-25
8314117 Nurtec Odt method of use 62 2034-02-27

Related